Literature DB >> 7719635

Recombinant cytokines for controlling mycobacterial infections.

L E Bermudez1, G Kaplan.   

Abstract

Knowing how mycobacteria exploit host cytokines to survive and which cytokines have important roles in host defense against mycobacteria should allow the use of these molecules in the treatment of mycobacterial infections. Both interleukin 2 and interferon gamma have been used to treat patients with leprosy, and granulocyte-macrophage colony-stimulating factor is presently being administered to AIDS patients infected with Mycobacterium avium.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7719635     DOI： 10.1016/s0966-842x(00)88864-2

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


  14 in total

1.  Opsonizing antibodies (IgG1) up-regulate monocyte proinflammatory cytokines tumour necrosis factor-alpha (TNF-alpha) and IL-6 but not anti-inflammatory cytokine IL-10 in mycobacterial antigen-stimulated monocytes-implications for pathogenesis.

Authors:  R Hussain; H Shiratsuchi; M Phillips; J Ellner; R S Wallis
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

2.  TNF-alpha antagonist therapy modify the tuberculin skin test response.

Authors:  Tulin Cagatay; Zeki Kilicaslan; Penbe Cagatay; Munevver Mertsoylu; Ziya Gulbaran; Reyhan Yildiz; Leyla Pur; Sevil Kamali; Ahmet Gul
Journal:  Rheumatol Int       Date:  2010-03-27       Impact factor: 2.631

3.  A role for tumour necrosis factor-alpha, complement C5 and interleukin-6 in the initiation and development of the mycobacterial cord factor trehalose 6,6'-dimycolate induced granulomatous response.

Authors:  Kerry J Welsh; April N Abbott; Shen-An Hwang; Jessica Indrigo; Lisa Y Armitige; Michael R Blackburn; Robert L Hunter; Jeffrey K Actor
Journal:  Microbiology (Reading)       Date:  2008-06       Impact factor: 2.777

4.  alpha(v)beta(3) integrin and bacterial lipopolysaccharide are involved in Coxiella burnetii-stimulated production of tumor necrosis factor by human monocytes.

Authors:  J Dellacasagrande; E Ghigo; S M Hammami; R Toman; D Raoult; C Capo; J L Mege
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

5.  Differential potentiation of anti-mycobacterial activity and reactive nitrogen intermediate-producing ability of murine peritoneal macrophages activated by interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha).

Authors:  K Sato; T Akaki; H Tomioka
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

6.  Mycobacterium avium infection in mice is associated with time-related expression of Th1 and Th2 CD4+ T-lymphocyte response.

Authors:  N Azouaou; M Petrofsky; L S Young; L E Bermudez
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

7.  Interleukin-10 stimulates Coxiella burnetii replication in human monocytes through tumor necrosis factor down-modulation: role in microbicidal defect of Q fever.

Authors:  E Ghigo; C Capo; D Raoult; J L Mege
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

8.  The modulating effects of proinflammatory cytokines interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha), and immunoregulating cytokines IL-10 and transforming growth factor-beta (TGF-beta), on anti-microbial activity of murine peritoneal macrophages against Mycobacterium avium-intracellulare complex.

Authors:  C Sano; K Sato; T Shimizu; H Kajitani; H Kawauchi; H Tomioka
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

9.  A study of serum malondialdehyde and cytokine in tuberculosis patients.

Authors:  Rashmi Kulkarni; Ajit Deshpande; Ravi Saxena; Kiran Saxena
Journal:  J Clin Diagn Res       Date:  2013-10-05

10.  Follow-up results of 702 patients receiving tumor necrosis factor-α antagonists and evaluation of risk of tuberculosis.

Authors:  Tulin Cagatay; Munevver Aydin; Sule Sunmez; Penbe Cagatay; Ziya Gulbaran; Ahmet Gul; Bahar Artim; Zeki Kilicaslan
Journal:  Rheumatol Int       Date:  2009-10-21       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.